In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.
US Food and Drug Administration approvals for targeted anticancer therapy are most often for specific types of cancer that possess specific driver mutations. However, the broad application of comprehensive genomic profiling has identified the presence of potential “druggable” driver mutations in malignancies for which FDA approval is not yet obtained.
Our panel will discuss several such clinical cases in detail and recommend a course of treatment based on the genomic profiles of the patients.
The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.
About The Series
The Virtual Molecular Tumor Board Series is an interactive and educational online program intended to highlight the key role that molecular tumor boards play in implementing precision oncology.
The series will underscore the collaborative nature of genomic medicine by assembling a multidisciplinary panel of experts who will meet virtually for four one-hour sessions. In each session, the panel will review the genomic and clinical evidence for anonymized patients who have had their tumors sequenced as part of clinical management. The panel will discuss each case and recommend a course of treatment.
Precision Oncology News would like to thank Clariifi for assistance in planning and executing this educational webinar series.